Pioneering Immune
Modifying Therapies

Developing next-generation T-Regulatory (Tregs) cell therapies and mRNA immunotherapies for Type 1 Diabetes, MS, ALS, and autoimmune/inflammatory diseases with collaborative partners.

Learn more Our science

ABOUT US

Pioneering Treg Therapies for Autoimmune Diseases

8-12

Years of Safety and Efficacy

No Serious Adverse Events associated with PTG-007.

>80

Autoimmune Diseases

Treatable with PTG-007

105

Patients Treated

with PTG-007

Harnessing the power of Treg cells

At Immuthera, the key to treating autoimmune diseases lies within the immune system itself. By harnessing and enhancing natural Treg cells, we develop therapies that don’t just suppress symptoms—they restore balance. From our clinically proven PTG-007 platform to cutting-edge CAR-Tregs and other novel modalities, we will build a future where autoimmune and neuroinflammatory diseases can be defeated.

More About Us

OUR SCIENCE

Treg Cell Technology

Maintaining Balance

T regulatory cells (Tregs) play a critical role in maintaining immune homeostasis. Immuthera is developing therapies that utilize Tregs to control and suppress harmful immune reactions in autoimmune diseases. Our PTG-007 platform serves as the foundation for developing a range of engineered Treg modalities.

Discover our Science

Watch the video

Type 1 diabetes

Presymptomatic (stage 1)

PTG-007+ / rituximab

Multiple sclerosis

Neuroinflammation

View Full Pipeline

01

PolTREG S.A. is the most clinically advanced company developing Tregulatory cell therapies for Autoimmune and Neuroinflammatory diseases.
02

Antion Biosciences SA is a cell and gene engineering biotechnology company based in Geneva (Switzerland), developing off-the-shelf therapies for the treatment of diseases with significant unmet medical needs.
03

Kinexum is an international healthcare consulting group specializing in regulatory strategy, clinical development, and commercialization.
04

McDermott Will & Emery is an industry leading lawfirm that partners with leaders around the world to fuel missions, knock down barriers and shape markets.
05

Incorporated in 1984, NOBLE Capital Markets, Inc. is operating as a S.E.C. & FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform.